Learn more about our Payment & Health Care Delivery Policy work.
AdvaMed® submitted a letter to CMS’s RFI on Medicare regarding ways to strengthen the Medicare Advantage program to align with the Vision for Medicare and CMS’ Strategic Pillars.
AdvaMed® submitted comments to CMS the CY 2023 End Stage Renal Disease (ESRD) Prospective Payment System.
The Advanced Medical Technology Association® (AdvaMed®), the world’s largest trade association representing medical device manufacturers, urged the U.S. Centers for Medicare & Medicaid Services (CMS) to issue its proposed Transitional…
AdvaMed® submitted a letter to Medicare Administrative Contractors, Novitas and First Coast Service Options, regarding proposed LCDs on Genetic Testing in Oncology.
AdvaMed® submitted comments to CMS on the Fiscal Year 2023 Hospital Inpatient Prospective Payment System proposed rule.
AdvaMed® submitted comments to the Center for Medicare and Medicaid Services (CMS) on its Radiation Oncology (RO) Model proposed rule proposing to indefinitely delay the start date of the RO…
AdvaMed® launched a Strategic Value Initiative to develop an approach and principles for assessing the value of medical technologies that can be adopted by health systems, payers, medtech companies, and…
AdvaMed® develops and advocates for sound payment policies that promote equitable patient access to diagnostic tests.
AdvaMed® develops strategies for improving Medicare coverage and payment systems and methodologies impacting patients, providers, and suppliers.
AdvaMed® submitted a letter regarding proposed local coverage determinations entitled “Skin Substitutes for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcer.”